ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE: 300254)
Health Care · Pharmaceuticals · CN
CN¥8.88
-1.11% today · -26.3% 1Y
ShanXi C&Y Pharmaceutical Group Co.,LTD. (SZSE: 300254) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $338.24M and employs 1,162 people.
Over the last twelve months the share price has lost 26.3%, trading between 6.93 and 15.20.
Tweenvest scores ShanXi C&Y Pharmaceutical Group Co.,LTD. across four factors: quality 65/100, value 39/100, growth 26/100. Its strongest factor is quality.
300254 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $338.24M
- Revenue (TTM)
- $125.10M
- P/E
- 122.65
- EPS
- 0.07
- Dividend yield
- —
- Beta (5Y)
- 0.44
- 52-week high
- CN¥15.20
- 52-week low
- CN¥6.93
- Avg volume (3M)
- —
- Shares outstanding
- 256.06M
- Employees
- 1,162
- Next earnings
- —
About ShanXi C&Y Pharmaceutical Group Co.,LTD.
ShanXi C&Y Pharmaceutical Group Co., Ltd. is a global pharmaceutical enterprise dedicated to the research, development, production, and distribution of a diverse range of medicines. Its operations span key markets including China, the United States, and Hong Kong, alongside other international regions. The company's extensive product catalog features specialized solutions for maternal and infant care, urological health, and infectious diseases, as well as traditional Chinese remedies and dermatological treatments. Additionally, it diversifies its offerings with tea bag products. Founded in 2005, the organization underwent a name change in September 2014, evolving from Shanxi C&Y Pharmaceutical Co., Ltd. to its current designation. ShanXi C&Y Pharmaceutical Group Co., Ltd. maintains its corporate headquarters in Shanghai, China.
- ISIN
- CNE1000016D0
- Founded
- 2005
- Listed since
- Aug 19, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.